Caitlin Douglass

A study published in the Journal of Clinical Oncology found that an EGFR inhibitor, erlotinib, was well tolerated in combination with whole-brain radiation therapy for patients with brain metastases from NSCLC.

Researchers discovered that the use of anamorelin among patients with advanced non-small cell lung cancer considerably helped more patients stabilize or gain lean body mass, a factor that consequently enables patients with cachexia to survive longer.